表紙
市場調查報告書
商品編碼
1045997

呼吸道融合病毒(RSV) (RSV) 診斷的全球市場 (2021-2026年):產業趨勢·佔有率·規模·成長·機會·預測

Respiratory Syncytial Virus (RSV) Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 142 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球呼吸道融合病毒(RSV) (RSV) 診斷的市場規模在2015年到2020年展現強力成長,從2021年到2026年間預計將以約10%的年複合成長率成長。

RSV 感染在新生儿期會變得嚴重,2 歲以下的兒童往往會出現嚴重的呼吸道症狀。再加上父母對兒童醫療保健的興趣日益濃厚,這是推動市場增長的關鍵因素之一。此外,早期診斷後的高存活率、診斷設備的可用性、醫療基礎設施的發展以及對住院嬰兒治療的優惠報銷政策也促進了市場的增長。

本報告提供全球呼吸道融合病毒(RSV) (RSV) 診斷的市場調查,彙整市場概要,市場規模的轉變·預測,產品·終端用戶·產業·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 序文

第2章 調查範圍·調查手法

第3章 摘要整理

第4章 簡介

第5章 全球呼吸道融合病毒(RSV) (RSV) 診斷市場

  • 市場概要
  • 市場實際成果
  • COVID-19影響

第6章 市場區隔:各產品

  • 直接熒光抗體 (DFA) 方法
  • 快速抗原診斷測試 (RADT)
  • 分子診斷
  • 色譜免疫分析
  • 診斷成像
  • 凝膠微滴
  • 流式細胞術
  • 其他

第7章 市場區隔:各終端用戶

  • 醫院·診所
  • 實驗室
  • 其他

第8章 市場區隔:各地區

  • 北美
  • 亞太地區
  • 歐洲
  • 南美
  • 中東·非洲

第9章 SWOT分析

第10章 價值鏈分析

第11章 波特的五力分析

第12章 價格分析

第13章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業的簡介
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • Coris BioConcept
    • DiaSorin Molecular LLC(DiaSorin Inc)
    • F. Hoffmann-La Roche AG
    • Merck KGaA
    • Quest Diagnostics Incorporated
    • Quidel Corporation
    • Thermo Fisher Scientific Inc.
目錄
Product Code: SR1020H56_Report

The global respiratory syncytial virus (RSV) diagnostics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Respiratory syncytial virus (RSV) is a viral infection of the lungs and respiratory tract, which can cause asthma, hospitalization, pneumonia, repeated infections, middle ear infection, and death. It can be diagnosed using blood tests, chest x-rays, a swab of secretions, and pulse oximetry by checking for signs like lung inflammation, white blood cell (WBC) count, and oxygen levels in the blood. Some of the commonly available treatment options for RSV are over-the-counter (OTC) medications, intravenous (IV) fluids, humidified oxygen, mechanical ventilation, and inhaled bronchodilators.

Respiratory Syncytial Virus (RSV) Diagnostics Market Trends:

  • RSV infection can be more serious during the neonatal period as children under two years of age tend to develop severe respiratory symptoms. This, in confluence with the rising focus of parents on child medical care, represents one of the crucial factors fostering the growth of the market. Moreover, the high survival rates after early diagnosis and the easy availability of diagnostic modalities act as other growth-inducing factors. Apart from this, the improving healthcare infrastructure and favorable reimbursement policies for the treatment of hospitalized infants are also contributing to market growth. Furthermore, the advent of advanced techniques like bio- and nanotechnology is facilitating the development of modern detection systems for RSV, such as western blot, enzyme-linked immunosorbent assay (ELISA), direct immunofluorescence, and real-time polymerase chain reaction (PCR). Besides this, governing agencies of numerous countries are funding research and development (R&D) projects for the development of new therapeutics. Other factors projected to drive the market are the growing number of clinical vaccine trials, the escalating demand for in-vitro diagnostics, rising incidences of childhood pneumonia and the increasing adoption of molecular diagnostics.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global respiratory syncytial virus (RSV) diagnostics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product and end use.

Breakup by Product:

  • Direct Fluorescent Antibody (DFA) Method
  • Rapid Antigen Diagnostic Test (RADTs)
  • Molecular Diagnostics
  • Chromatographic Immunoassay
  • Diagnostic Imaging
  • Gel Microdroplets
  • Flow Cytometry
  • Others

Breakup by End Use:

  • Hospitals and Clinics
  • Laboratory
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., Coris BioConcept, DiaSorin Molecular LLC (DiaSorin Inc), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics Incorporated, Quidel Corporation and Thermo Fisher Scientific Inc. Key Questions Answered in This Report:

  • How has the global respiratory syncytial virus (RSV) diagnostics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global respiratory syncytial virus (RSV) diagnostics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global respiratory syncytial virus (RSV) diagnostics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Respiratory Syncytial Virus (RSV) Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Direct Fluorescent Antibody (DFA) Method
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Rapid Antigen Diagnostic Test (RADTs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Molecular Diagnostics
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Chromatographic Immunoassay
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Diagnostic Imaging
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Gel Microdroplets
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Flow Cytometry
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by End Use

  • 7.1 Hospitals and Clinics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Laboratory
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Becton, Dickinson and Company
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 bioMerieux SA
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bio-Rad Laboratories Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Coris BioConcept
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 DiaSorin Molecular LLC (DiaSorin Inc)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 F. Hoffmann-La Roche AG
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 SWOT Analysis
    • 13.3.8 Merck KGaA
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Quest Diagnostics Incorporated
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Quidel Corporation
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Thermo Fisher Scientific Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis